Science Daily: Pharmacology News

JULY 12, 2025

This breakthrough holds major promise for studying neurological diseases like Alzheimer’s and Parkinson’s, creating more accurate models for drug testing, and eventually even enabling neuron replacement therapies.

Research

Science Daily: Pharmacology News

JULY 25, 2025

By decoding these natural chemical defenses, scientists could open a new path toward innovative drug therapies, though challenges remain in producing the compounds at scale. These complex molecules, which cause disorientation in ants, interact with human neuroreceptors linked to pain and cognition.

Drug Research

Drug Target Review

FEBRUARY 10, 2025

In the rapidly advancing field of cell therapies, Dr Jason Bock has emerged as a leader, known for his innovative approach to optimising the development process. With over 25 years of experience in therapeutics, Bock has played a pivotal role in shaping the future of cell therapies, particularly through his work at CTMC.

Therapies

BioPharma Drive: Drug Pricing

JUNE 11, 2025

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.

Packaging

Science Daily: Pharmacology News

JULY 5, 2025

In mouse models, restoring the protein’s function with a targeted copper supplement dramatically rescued movement, hinting at a future therapy that could slow or halt the disease in people.

Therapies

Drug Target Review

JULY 19, 2025

Maria Knaub, Senior Medical Affairs Operations Lead at Terumo Blood and Cell Technologies (Terumo BCT), brings a unique blend of frontline experience and scientific expertise to the fore of cell therapy innovation. I try to bridge the gap between research and patient access, helping to advance life-saving therapies from bench to bedside.

Therapies

BioPharma Drive: Drug Pricing

JULY 9, 2025

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. subsidiary of Merck KGaA, is the founder of radioligand therapy developer Actithera. You can unsubscribe at anytime.

Drugs

Science Daily: Pharmacology News

JUNE 16, 2025

In a groundbreaking trial, a single dose combined with therapy significantly reduced emotional suffering, and these effects often lasted over two years. Psilocybin, the active ingredient in magic mushrooms, might just revolutionize how depression and anxiety are treated in cancer patients.

Therapies

Drugs.com

JUNE 18, 2025

WEDNESDAY, June 18, 2025 — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall Street Journal reported.

Therapies

BioPharma Drive: Drug Pricing

AUGUST 4, 2025

Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full capsids.

Therapies

Covalent Modifiers

MAY 7, 2025

5c01712 Covalent small molecule drugs have emerged as a crucial support in precision therapy due to their high selectivity and robust potency. These findings suggest that our work could potentially expand the target space of covalent drugs and promote precision therapy by harnessing the power of the CoDELs.

DNA

Crown Bioscience

JULY 17, 2025

Both the novel and supplemental oncology approvals reflected recent developmental innovations, including an increased focus on targeted, immunologically driven, and personalized oncology therapies, targeting a broad range of cancers.

FDA Approval

Drugs.com

JULY 31, 2025

THURSDAY, July 31, 2025 — There’s potentially exciting news from a trial conducted in monkeys: A single shot of gene therapy given to newborn monkeys appears to shield them from HIV, the virus that causes AIDS, for at least three.

Virus

The Pharma Data

JUNE 25, 2025

Biogen Reports Promising Interim Phase 1 Results for Salanersen in Spinal Muscular Atrophy, Prepares for Registrational Trials Biogen has announced encouraging topline results from its Phase 1 clinical trial evaluating salanersen (BIIB115/ION306) , an investigational antisense oligonucleotide (ASO) therapy for spinal muscular atrophy (SMA).

Therapies

The Pharma Data

JUNE 26, 2025

FDA Approves Streamlined Monitoring Requirements and REMS Program Removal for Bristol Myers Squibb’s CAR T Cell Therapies Breyanzi and Abecma, Marking Milestone Toward Expanding Access to Cancer Treatment In a significant regulatory development, Bristol Myers Squibb announced that the U.S.

FDA Approval

Covalent Modifiers

AUGUST 1, 2025

This approach provides a targeted endogenous protein degradation strategy with real-time monitoring, offering a powerful and generalizable platform for next-generation PROTAC design, the advancement of peptide-based therapeutics, and the rational optimization of cancer therapy.

Targeted Protein Degradation

Drug Target Review

APRIL 30, 2025

In the rapidly evolving field of cell and gene therapy (CGT), the ability to manage complex biological data, optimise manufacturing processes, and accelerate drug discovery is crucial. How AI is solving CGTs biggest challenges Cell and gene therapy is inherently complex. Kosten Digital was established to bridge this gap.

Drugs

Drug Target Review

JUNE 16, 2025

Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.

Disease

Drug Target Review

AUGUST 6, 2025

Esperion’s approved therapies are already based on this mechanism. Image credit: Vector_Leart / Shutterstock From heart disease to liver inflammation ACLY sits at the crossroads of sugar and fat metabolism, converting citrate into acetyl-CoA – a critical building block for lipid synthesis. Yet something new was starting to surface.

Therapies

Drug Target Review

JULY 21, 2025

This absence of objective measures contributes to the variability in patient response to treatments, complicating efforts to produce standardised therapies. Moreover, regulatory pathways also change considerably based on the type of therapy – and guidance is sparse.

Drug Development

The Pharma Data

AUGUST 1, 2025

European Commission Greenlights AUCATZYL®: AGC Biologics Marks 10th Regulatory Approval with Autolus’ CAR-T Therapy AGC Biologics , a global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies, has reached another significant milestone.

Therapies

Broad Institute

JANUARY 9, 2025

Scientists engineer CRISPR enzymes that evade the immune system By Allessandra DiCorato January 9, 2025 Breadcrumb Home Scientists engineer CRISPR enzymes that evade the immune system The new genome-editing tools could lead to safer, more efficient gene therapies. Lisa Yang and Hock E. Tan Molecular Therapeutics Center at MIT.

Engineering

Science Daily: Pharmacology News

APRIL 22, 2025

A new paper showcases the power of scalable protein engineering combined with machine learning to boost progress in the field of gene and cell therapy. Genome editing has advanced at a rapid pace with promising results for treating genetic conditions -- but there is always room for improvement.

Engineering

The Pharma Data

JUNE 24, 2025

This alliance aims to address mounting challenges in the development and commercialization of mAb therapies and gene therapies, particularly those involving AAV vectors. To date, more than 160 monoclonal antibody therapies targeting nearly 100 disease-related proteins have received regulatory approval globally.

Therapies

Science Daily: Pharmacology News

JUNE 30, 2025

Even more exciting: when targeted therapies were applied, the immune assault weakened. Scientists have achieved an unprecedented look into how the human immune system attacks a transplanted pig kidney, using spatial molecular imaging to map immune activity down to the cellular level.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 8, 2025

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.

Trials

The Pharma Data

JUNE 13, 2025

Standard single-target CD19-directed CAR T-cell therapies typically enable long-term remissions in roughly 40% of patients, emphasizing a significant unmet need for new and more effective treatment strategies. Among patients who had previously undergone two or more lines of therapy (n = 12), the ORR was 92% and the CRR was 75%.

Therapies

Chemical Biology and Drug Design

MAY 12, 2025

This article outlines the current antiretroviral therapy and its adverse effects but also CRISPR/Cas technology. Its applicability extends to various organisms, making it increasingly prevalent in the medical field, where it shows great promise in investigating viral infections, cancer, and genetic disorders.

Treatment

Chemical Biology and Drug Design

JANUARY 20, 2025

This study emphasizes the distinct role of the peptide, linker, and drug for optimal PDC activity and highlights the need to carefully match components when assembling PDCs as targeted therapies.

Small Molecule

Chemical Biology and Drug Design

JULY 3, 2025

Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities.

Drug Development

Drug Target Review

APRIL 7, 2025

As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.

Clinical Development

Drug Target Review

JUNE 9, 2025

“This experience underscored the gaps in rare disease innovation, motivating me to lead Alltrna, a company pioneering engineered tRNA therapies to address a broad range of genetic diseases in a profound way unlike any other genetic modality.”

Disease

Drug Target Review

JUNE 6, 2025

At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies. Meet Dr Ebrahim Delpassand Dr Ebrahim S.

Therapies

Chemical Biology and Drug Design

JANUARY 22, 2025

The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.

Therapies

Drug Target Review

JULY 30, 2025

Radioligand therapy (RLT) has emerged as a powerful modality in oncology, offering highly targeted delivery of radiation to cancer cells while sparing healthy tissues. While Molecular Partners are the leaders in the development of DARPins, Orano Med is the leader in 212Pb-based radioligand therapy (RLT),” Julien explained. “By

Clinical Trials

Broad Institute

FEBRUARY 27, 2025

An ancient RNA-guided system could simplify delivery of gene editing therapies By Corie Lok February 27, 2025 Breadcrumb Home An ancient RNA-guided system could simplify delivery of gene editing therapies The programmable proteins are compact, modular, and can be directed to modify DNA in human cells.

RNA

BioPharma Drive: Drug Pricing

JUNE 30, 2025

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

Therapies